Pharmacokinetics and pharmacodynamics of subcutaneous interleukin-2 in HIV-infected patients

Pharmacotherapy

Volumn 16, Issue 5 I, 1996, Pages 754-759

  Piscitelli, Stephen C ^a,d   Wells, Mary J ^a   Metcalf, Julia A ^b   Baseler, Michael ^c   Stevens, Randy ^c   Davey Jr , Richard T ^b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c SAIC FREDERICK INC   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT INTERLEUKIN 2;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PHARMACODYNAMICS; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AREA UNDER CURVE; FEMALE; FEVER; HALF-LIFE; HIV INFECTIONS; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-2; MALE; METABOLIC CLEARANCE RATE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0029766860     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Hirsch MS, DíAquila RT. Therapy for human immunodeficiency virus infection. N Engl J Med 1993;328:1686-95.
2. Sande MA, Carpenter CC, Cobbs CG, Holmes KK, Sanford JP. Antiretroviral therapy for adult HIV-infected patients. JAMA 1993;270:2583-9.
3. Rook AH, Hooks JJ, Quinnan GV, et al. Interleukin-2 enhances the natural killer cell activity of acquired immunodeficiency syndrome patients through a γ-interferon-dependent mechanism. J Immunol 1985;134:1503-7.
4. Rook AH, Masur H, Lane HC, et al. Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immunodeficiency syndrome. J Clin Invest 1985;72:398-403.
5. Kovacs JA, Baseler M, Dewar R, et al. Increases in CD4+ lymphocytes with intermittent courses of continuous interleukin-2 infusions in patients with human immunodeficiency virus infection: a preliminary study. N Engl J Med 1995;332:567-75.
6. Schwartz DH, Skowron G, Merigan TC. Safety and effects of interleukin-2 plus zidovudine in asymptomatic individuals infected with the human immunodeficiency virus. J Acquir Immune Defic Syndr 1991;4:11-23.
7. D'Argenio DZ, Schumitzky A. ADAPT II user's guide. Los Angeles: Biomedical Simulations Resource, University of Southern California, 1990.
8. Yamaoka K, Nakagawa T, Uno T. Application of Akaike's information criterion in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 1978;6:165-75.
9. Gibaldi M, Perrier D. Pharmacokinetics, 2nd ed. New York: Marcel Dekker, 1982.
10. Piscitelli SC, Zamboni WC, Wells M, et al. Co-modelling of interleukin-2 concentrations as a function of soluble IL-2 receptors in HIV-infected patients [abstr]. Pharmacotherapy 1995;15:389.
11. Ziegler LD, Palazzolo P, Cunningham J, et al. Phase I trial of murine monoclonal antibody L6 in combination with subcutaneous interleukin-2 in patients with advanced carcinoma of the breast, colorectum, and lung. J Clin Oncol 1992;10:1470-8.
12. Whitehead RP, Ward D, Hemingway L, Hemstreet GP, Bradley E, Konrad M. Subcutaneous recombinant interleukin-2 in a dose escalating regimen in patients with metastatic renal cell adenocarcinoma. Cancer Res 1990;50:6708-15.
13. Konrad MW, Hemstreet G, Hersh EM, et al. Pharmacokinetics of recombinant interleukin-2 in humans. Cancer Res 1990;50:2009-17.
14. Gustavson LE, Nadeau RW, Oldfield NF. Pharmacokinetics of teceleukin (recombinant human interleukin-2) after intravenous or subcutaneous administration to patients with cancer. Journal of Biological Response Modifiers 1989;8:440-9.
15. Davey RT Jr, Wells MJ, Piscitelli, SC, et al. Subcutaneous administration of interleukin-2 in HIV-1 infected individuals [abstr]. Clin Infect Dis 1994;19:610.
16. Mittelman A, Puccio C, Gafney E, et al. A phase I pharmacokinetic study of recombinant human tumor necrosis factor administered by a 5-day continuous infusion. Invest New Drugs 1992;10:183-90.
17. Saks S, Rosenblum M. Recombinant human TNF-alpha: preclinical studies and results from early clinical trials. Immunol Semin 1992;56:567-87.